Phase 4 N=115 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
Turner's Syndrome
Primary: Height SDS at Year 4 — -1.35; -2.44 standard deviation score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=780 Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib
Infections, Streptococcal
Primary: Antibody Concentrations Against Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (Anti-1, -4, -5, -6B, -7F, -9V, -14, -18C, -19F and -23F) - Primary…
Phase 2 N=12 Study of EB-001 in Facial Scar Reduction
Mohs Surgery
Primary: Assessment of Visual Analog Scale (VAS) Change (Values From 0 (Worst) to 10 (Best)) — 0; 50 Percentage reporting improvement
Phase 2 N=117 A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Change From Baseline in Forced Vital Capacity (FVC) [% Predicted] — -2.5; -4.8 Percentage of predicted FVC — p=0.0014
Phase 3 N=60 Magnesium vs Placebo for Tonsillectomy
Pain
Primary: Postoperative Pain — 30; 45 scores on a scale*minutes
Phase 4 N=28 Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
Influenza
Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants
Phase 2 N=419 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
Low Bone Mineral Density · Postmenopausal Osteoporosis
Primary: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine — -0.1; 4.1; 7.1; 5.4 percent change — p=< 0.0001
Phase 3 N=1,436 A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
Influenza
Primary: Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or Placebo — 53.7; 80.2 hours — p=<0.0001
Phase 1 N=16 Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)
Hepatitis C
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Dosing to Time of Last Measurable Concentration (AUC0-last) of Uprifosbuvir (MK-3682) — 8.55; 4.23 uM*hr
Phase 4 N=33 Acamprosate vs. Placebo in Bipolar Alcoholics
Alcohol Dependence · Bipolar Disorder
Primary: Time to First Drink (Days) — 16.5; 8.0 Days
Phase 3 N=455 Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Conjunctival Staining — -1.9; -1.8; -1.2 score on a scale
N/A N=662 Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
Cystoid Macular Edema
Primary: Post-operative Clinical Findings of Cystoid Macular Edema — 8.85; 8.95 mm
Phase 3 N=210 Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali
Infections, Streptococcal
Primary: Number of Subjects With Grade 3 Adverse Events (Solicited and Unsolicited) — 3; 1; 2 Participants
Phase 2 N=692 The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)
Pneumococcal Infections
Primary: Percentage of Participants With an Adverse Event — 75.1; 68.3; 65.7 Percentage of Participants
Phase 2 N=60 ALS Reversals - Lunasin Regimen
ALS (Amyotrophic Lateral Sclerosis)
Primary: Change in Revised ALS Functional Rating Scale (ALSFRS-R) — 0.44 points per month — p=0.99